Positioning and Usefulness of Biomarkers in Inflammatory Bowel Disease
Open accessThe DOI matches its Crossref record; 137 of the 137 references it cites were found in a registry or an index.
Abstract
Background: Mucosal healing (MH) was proposed to be an ideal treatment goal for patients with inflammatory bowel disease (IBD). Instead of endoscopy to confirm MH, biomarkers are frequently used and have become an indispensable modality for the clinical examination of patients with IBD. Summary: Common biomarkers of IBD include C-reactive protein (CRP), erythrocyte sedimentation rate, antineutrophil cytoplasmic antibodies, anti-Saccharomyces cerevisiae antibodies, leucine-rich α2 glycoprotein, fecal calprotectin (FCP), and the fecal immunochemical test. Biomarkers play five major roles in the management of IBD: (1) diagnosing and distinguishing between IBD and non-IBD or ulcerative colitis and Crohn’s disease; (2) predicting treatment response, especially before administrating biologics; (3) monitoring and grasping endoscopic or histological disease activity; (4) replacing endoscopy for diagnosing MH, including endoscopic and histological remission; and (5) predicting recurrence before disease activity appears through symptoms. Many reports have demonstrated the usefulness of CRP and FCP for those five roles; however, they have limitations for diagnosing MH or predicting treatment response. In general, FCP has better ability in those positions than CRP; additionally, leucine-rich α2 glycoprotein can diagnose endoscopic disease activity better than CRP. The novel biomarker, prostaglandin E-major urinary metabolite, and anti-αvβ6 antibody are expected to be noninvasive and reliable biomarkers; however, more evidence is required for future studies. Oncostatin M and microRNA are also prospects, in addition to other familiar and novel biomarkers. Key Messages: Each biomarker has a useful feature; therefore, we should consider their features and use appropriate biomarkers for the five roles to enable noninvasive and smooth management of IBD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“One of the primary advantages of the AI-aided fusion multimodal approach is the ability to identify and understand specific and interconnected biological alterations, enabling early and improved disease diagnosis and outcome.85”
From Artificial intelligence and endo-histo-omics: new dimensions of precision endoscopy and histology in inflammatory bowel disease (2024) · cites this paper as [85]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Calcium's Role in Mechanotransduction during Muscle Development
Benavides Damm, T., & Egli, M. (2014) · Cellular Physiology and Biochemistry · doi:10.1159/000356667 · Cited by 14,502
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859
Ng, S. C., Shi, H. Y., Hamidi, N., Underwood, F. E., Tang, W., Benchimol, E. I., Panaccione, R., Ghosh, S., Wu, J. C. Y., Chan, F. K. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32448-0 · Cited by 6,087
C-reactive protein: a critical update
Pepys, M. B., & Hirschfield, G. M. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18921 · Cited by 3,503
Turner, D., Ricciuto, A., Lewis, A., D’Amico, F., Dhaliwal, J., Griffiths, A. M., Bettenworth, D., Sandborn, W. J., Sands, B. E., Reinisch, W., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2020.12.031 · Cited by 2,911
Magro, F., Gionchetti, P., Eliakim, R., Ardizzone, S., Armuzzi, A., Barreiro-de Acosta, M., Burisch, J., Gecse, K. B., Hart, A. L., Hindryckx, P., et al. (2017) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjx008 · Cited by 1,910
Peyrin-Biroulet, L., Sandborn, W., Sands, B. E., Reinisch, W., Bemelman, W., Bryant, R. V., D'Haens, G., Dotan, I., Dubinsky, M., Feagan, B., et al. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.233 · Cited by 1,844
Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort
Frøslie, K. F., Jahnsen, J., Moum, B. A., & Vatn, M. H. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.051 · Cited by 1,121
Laboratory markers in IBD: useful, magic, or unnecessary toys?
Vermeire, S., Van Assche, G., & Rutgeerts, P. (2006) · Gut · doi:10.1136/gut.2005.069476 · Cited by 952
Colombel, J. F., Rutgeerts, P., Reinisch, W., Esser, D., Wang, Y., Lang, Y., Marano, C. W., Strauss, R., Oddens, B. J., Feagan, B. G., et al. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.06.054 · Cited by 919
Cited by
Ulcerative colitis: clinical biomarkers, therapeutic targets, and emerging treatments
Wangchuk, P., Yeshi, K., & Loukas, A. (2024) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2024.08.003 · Cited by 333
Díez-Martín, E., Hernández-Suárez, L., Muñoz‐Villafranca, C., Martin–Souto, L., Astigarraga, E., Ramirez‐Garcia, A., & Barreda‐Gómez, G. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137062 · Cited by 135
“Additionally, calprotectin found in fecal samples can provide a measure of specific intestinal inflammation, whereas that obtained from other fluids offers a more general measure of body inflammation [223].”
InfluentialBiomarkers in inflammatory bowel disease: a practical guide
Clough, J., Colwill, M., Poullis, A. P., Pollok, R., Patel, K., & Honap, S. (2024) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848241251600 · Cited by 118
“13 For clinicians, there are also further considerations such as availability, turn-around time for testing and robustness of the analytic method used.”
MethodJiang, W. J., Yin, J., Han, M., He, W., Zhao, Y., Hu, J., Wang, M., Wang, S., Xu, J., Deng, C., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s518155 · Cited by 88
“43 Detecting the expression of N4BP3 in the blood from IBD patients and normal populations, analyzing the correlation between the expression of N4BP3 in the blood and IBD, which may provide a new method for the diagnosis of IBD.”
Iacucci, M., Santacroce, G., Zammarchi, I., Maeda, Y., Del Amor, R., Meseguer, P., Kolawole, B. B., Chaudhari, U., Di Sabatino, A., Danese, S., et al. (2024) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(24)00053-0 · Cited by 73
Inflammatory bowel diseases: pathological mechanisms and therapeutic perspectives
Yang, X., Guo, H., & Zou, M. (2026) · Molecular Biomedicine · doi:10.1186/s43556-025-00395-z · Cited by 92
“Furthermore, host– microbial interactions have been systematically inter-rogated, identifying specific microbial species and their bioactive metabolites as actionable targets for precision intervention [563, 564].”
Aging amplifies a gut microbiota immunogenic signature linked to heightened inflammation
Caetano‐Silva, M. E., Shrestha, A., Duff, A. F., Kontic, D., Brewster, P. C., Kasperek, M. C., Lin, C., Wainwright, D. A., Hernández‐Saavedra, D., Woods, J. A., et al. (2024) · Aging Cell · doi:10.1111/acel.14190 · Cited by 62
“Next, we measured calprotectin, a critical cytoplasmic protein found in innate immune cells, including neutrophils and macrophages, and a well-known biomarker of immune cell infiltration and intestinal inflammation in inflammatory bowel disease (IBD) patients (Park, 2020; Sakurai & Saruta, 2022).”
MethodDiagnosis and management of inflammatory bowel disease
Li, L., Cheng, R., Wu, Y., Lin, H., Gan, H., & Zhang, H. (2024) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.12626 · Cited by 58
Altered fecal bile acid composition in active ulcerative colitis
Sommersberger, S., Gunawan, S., Elger, T., Fererberger, T., Loibl, J., Huss, M., Kandulski, A., Krautbauer, S., Müller, M., Liebisch, G., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01971-4 · Cited by 47
“In this study, C-reactive protein (CRP), as the most used systemic inflammatory marker, was not included [25–27].”
BackgroundPrecision Medicine in Inflammatory Bowel Disease: A Spotlight on Emerging Molecular Biomarkers
Meštrović, A., Perković, N., Božić, D., Kumrić, M., Vilović, M., & Božić, J. (2024) · Biomedicines · doi:10.3390/biomedicines12071520 · Cited by 45
“Recent studies have shed light on the role of Leucine-Rich Alpha-2 Glycoprotein (LRG), an emerging biomarker and potential therapeutic target in IBD [21].”
BackgroundInfluentialRole of C-reactive protein in disease progression, diagnosis and management
Ali, S., Zehra, A., Khalid, M. U., Hassan, M., & Shah, S. I. A. (2023) · Discoveries · doi:10.15190/d.2023.18 · Cited by 47
The Role of Calprotectin in the Diagnosis and Treatment of Inflammatory Bowel Disease
Wang, W., Cao, W., Zhang, S., Chen, D., & Liu, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051996 · Cited by 46
Biomarkers in IBD: What to Utilize for the Diagnosis?
Renata D'Incà, & Sturniolo, G. (2023) · Diagnostics · doi:10.3390/diagnostics13182931 · Cited by 32
Current Approaches for Monitoring of Patients with Inflammatory Bowel Diseases: A Narrative Review
Vitello, A., Maida, M. F., Shahini, E., Macaluso, F. S., Orlando, A., Grova, M., Ramai, D., Serviddio, G., & Facciorusso, A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13041008 · Cited by 27
“…response to treatment differ from patient to patient and based on different clinical scenarios, similar results have been observed in post-hoc RCTs and real-life observational studies with biological drugs (i.e., vedolizumab, ustekinumab) and small molecules (i.e., tofacitinib) [7,23,28].”
BackgroundResultSystemic immune-inflammation index as a potential biomarker to monitor ulcerative colitis
Jin, Y., Deng, F., Tan, Y., Zhou, B., & Liu, D. (2023) · Current Medical Research and Opinion · doi:10.1080/03007995.2023.2257599 · Cited by 28
Berberine: Potential preventive and therapeutic strategies for human colorectal cancer
Feng, Y., Lu, J., Jiang, J., Wang, M., Guo, K., & Lin, S. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.4033 · Cited by 24
“111 The deposited OSM will accelerate the process of numerous inflammatory cells infiltrating the mucosa and contribute to intestinal fibrosis.”
BackgroundFecal, Blood, and Urinary Biomarkers in Inflammatory Bowel Diseases
Bencardino, S., D’Amico, F., Zilli, A., Parigi, T. L., Allocca, M., Fiorino, G., Danese, S., & Furfaro, F. (2024) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2024.00017 · Cited by 29
Sivridaş, M., Creemers, R. H., Wong, D. R., Boekema, P. J., Römkens, T. E. H., Gilissen, L. P. L., Bodegraven, A. A. V., Loeff, F. C., Rispens, T., & Derijks, L. J. J. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15030972 · Cited by 20
“Indeed, biochemical remission seems to be a better predictor of mucosal inflammation [29].”
BackgroundCurrent perspectives on fecal microbiota transplantation in inflammatory bowel disease
Singh, A., Midha, V., Chauhan, N. S., & Sood, A. (2024) · Indian Journal of Gastroenterology · doi:10.1007/s12664-023-01516-8 · Cited by 21
“More recently, the fecal metabolome has been described as a vital biomarker for IBD [86, 87].”
Residual Disease Burden Among European Patients With Inflammatory Bowel Disease: A Real-World Survey
Burisch, J. M., Hart, A. L., Sturm, A., Rudolph, C., Meadows, R., Jus, A., Dawod, F., Patel, H., & Armuzzi, A. (2024) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izae119 · Cited by 27
Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches
Centanni, L., Cicerone, C., Fanizzi, F., D’Amico, F., Furfaro, F., Zilli, A., Parigi, T. L., Peyrin‐Biroulet, L., Danese, S., & Allocca, M. (2025) · Pharmaceuticals · doi:10.3390/ph18010078 · Cited by 23
“Persistent elevation of CRP or FC during treatment should prompt clinicians to re-evaluate therapeutic strategies, as these biomarkers are indicative of ongoing inflammation even in asymptomatic patients [25].”
InfluentialFrom Homeostasis To Inflammation To Autoimmunity: The Potential Impact of CRP
Ahmed, M. J., Yuan, P., Lei, J.-G., Tang, Z.-M., Yang, Z.-R., Potempa, L. A., Wang, H., & Li, H. (2025) · Inflammation · doi:10.1007/s10753-025-02303-7 · Cited by 23
Wu, Y., & Shen, J. (2024) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2024.10.003 · Cited by 23
Mendes‐Frias, A., Moreira, M., Vieira, M. C., Gaifem, J., Costa, P., Lopes, L., & Silvestre, R. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1367998 · Cited by 15
Jin, X., Wang, Q., Xie, T., Xu, S., Chen, D.-A., Cao, G.-Y., Wang, G., Wang, J., & Zhen, L. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c02545 · Cited by 17
Mureşan, S., & SLEVIN, M. A. (2024) · Cureus · doi:10.7759/cureus.59009 · Cited by 22
MicroRNAs in inflammatory bowel disease: What do we know and what can we expect?
Oliveira, E. C. S. D., Quaglio, A. E. V., Grillo, T. G., Stasi, L. C. D., & Sassaki, L. Y. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i16.2184 · Cited by 18
“Regarding IBD monitoring, few biomarkers for disease activity, such as fecal calprotectin, have been validated[30,31] and therefore colonoscopy is needed to visualize the intestinal mucosa.”
SpA plus IBD or IBD plus SpA: Does commutative property apply?
Carubbi, F., Alunno, A., Viscido, A., Baraliakos, X., Mariani, F. M., Ruscio, E. D., Altieri, P., & Ferri, C. (2023) · Autoimmunity Reviews · doi:10.1016/j.autrev.2023.103443 · Cited by 13
Ripa, J. D., Ghumro, S. A., Field, M. A., Smithson, J., & Wangchuk, P. (2025) · Pharmaceuticals · doi:10.3390/ph18101536 · Cited by 17
Fu, Q., Vegesna, M., Sundararaman, N., Damoc, E., Arrey, T. N., Pashkova, A., Mengesha, E., Debbas, P., Joung, S. Y., Li, D., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202409446 · Cited by 16
Tews, H. C., Elger, T., Gunawan, S., Fererberger, T., Sommersberger, S., Loibl, J., Huss, M., Liebisch, G., Müller, M., Kandulski, A., et al. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01929-6 · Cited by 14
“Acetate, propionate and butyrate positively correlated with serum CRP of UC patients, which is a useful marker to monitor disease activity in IBD [50].”
BackgroundTeixeira, B. R. F., Gonçalves, H. M. R., & Martins‐Lopes, P. (2025) · Biosensors · doi:10.3390/bios15080513 · Cited by 13
Chen, B., Li, D., Tong, B., Wang, L., Lin, H., Xu, H., & Hu, S. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124394 · Cited by 10
Orejudo, M., Gómez, M. J., Riestra, S., Rivero, M., Gutiérrez, A., Rodríguez–Lago, I., Fernández-Salazar, L. I., CEBALLOS, D. S., Benítez, J. M., Aguas, M., et al. (2025) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2025.1595884 · Cited by 13
Pehrsson, M., Alexdóttir, M. S., Karsdal, M. A., Thakker, P., & Mortensen, J. H. (2023) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2023.2212158 · Cited by 12
Motwani, K. K., Alizadeh, M. A., Abutaleb, A., Grossman, J., Wellington, J., Cross, R. K., SPARC-IBD investigators, Russ, K. B., Bewtra, M., Lewis, J. D., et al. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08421-w · Cited by 7
Deep mucosal healing in ulcerative colitis: how deep is better?
Jin, X., You, Y., Ruan, G., Zhou, W., Ji, L., & Li, J. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1429427 · Cited by 9
Araújo, M. R., Mendes‐Frias, A., & Silvestre, R. (2026) · Biology of Sex Differences · doi:10.1186/s13293-026-00857-1 · Cited by 12
Circulatory resistin levels in inflammatory bowel disease: a systematic review and meta-analysis
Behnoush, A. H., Maroufi, S. P., Reshadmanesh, T., Kia, Y. M., Norouzi, M., Mohammadi, S. M., Klisic, A. N., & Khalaji, A. (2024) · BMC Gastroenterology · doi:10.1186/s12876-024-03199-7 · Cited by 8
“This is primarily due to its ability to differentiate patients in recovery from healthy individuals, providing more accurate information about the disease progression [58].”
BackgroundLu, F., Huang, X., Zhang, K., Yin, X., Lv, Y., Du, Y., Zhou, Q., Min, J.-Y., & Cheng, C.-E. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s519545 · Cited by 10
Limketkai, B. N., Maas, L., Krishna, M., Dua, A., DeDecker, L. C., Sauk, J. S., & Parian, A. M. (2023) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izad127 · Cited by 7
AlRasheed, H. A., Abdallah, M. S., El‐Khateeb, E., Kamal, M., Alrubia, S., Alsegiani, A. S., Ahmed, T. I., & Bahaa, M. M. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s522755 · Cited by 7
“58 CRP is a major acute-phase protein, and while its baseline level is typically around 1 mg/l, it increases rapidly during the acute phase of infection or inflammation.”
Zhang, H., Shen, Y., Cao, B., Zheng, X., Zhao, D., Hu, J., & Wu, X. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s491043 · Cited by 5
“31 False positive FC values may arise in patients with inflammatory polyps within 3 months post-surgery, within 2 weeks post-colonoscopy, and in those using nonsteroidal anti-inflammatory drugs or proton-pump inhibitors.”
Pehrsson, M., Domislović, V., Alexdóttir, M. S., Brinar, M., Karsdal, M. A., Barišić, A., Krznarić, Ž., & Mortensen, J. H. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm13010021 · Cited by 6
“With proper validation, serological biomarkers of tissue remodeling could act as supportive tools for patient monitoring, stratification, and clinical trial enrichment and reduce the need for invasive endoscopy [21,22].”
MethodFu, Q., Vegesna, M., Sundararaman, N., Damoc, E., Arrey, T. N., Pashkova, A., Mengesha, E., Debbas, P., Joung, S. Y., Li, D., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.20.586018 · Cited by 6
Comparative Value of CRP and FCP for Endoscopic and Histologic Remissions in Ulcerative Colitis
Bakkaloğlu, O. K., Sen, G., Kepil, N., Eşkazan, T., Kurt, E. A., Onal, U., Candan, S., Balamir, M., Hatemı, İ., Erzin, Y. Z., et al. (2024) · Diagnostics · doi:10.3390/diagnostics14202283 · Cited by 8
“Biomarkers such as CRP and FCP are frequently used for this purpose [21].”
BackgroundBravo‐Núñez, Á., Valéro, R., & Reboul, E. (2024) · Nutrition Research Reviews · doi:10.1017/s0954422424000155 · Cited by 8
Liu, X., Pan, L.-X., Pei, J.-X., Pu, T., Wen, H.-T., & Zhao, Y. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i18.104206 · Cited by 7
Gavrilescu, O., Popa, I. V., Dranga, M., Mihai, R., Prelipcean, C. C., & Mihai, C. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113609 · Cited by 5
“For this reason, the international community of GI experts is still searching for the ideal biomarker (non-invasive, non-expensive, readily available) to revolutionize disease monitoring in UC [5].”
BackgroundRole of endoscopic ultrasound as a predictor of histological healing in ulcerative colitis
Tian, J. L., Wang, W., Liu, Y., Zhang, X., Zhao, H., & Qu, H. (2025) · Annals of Medicine · doi:10.1080/07853890.2025.2499961 · Cited by 5
“CRP is a recognized bio-marker for evaluating inflammatory processes [23], and a meta-analysis performed by Mosli et al. indicated that it could predict endoscopic inflammation in patients with UC [24].”
Limsrivilai, J., Lai, A. Y.-H., Li, S. T. H., Abdullah, M., Ali, R. A. R., Aniwan, S., Bui, H. H., Chou, J., Hilmi, I. N., Lim, W. C., et al. (2025) · Intestinal Research · doi:10.5217/ir.2024.00085 · Cited by 10
“CRP is not specific to IBD 16 and less sensitive to inflammatory activity than FC. 17 Therefore, the FC test is becoming the preferred option where it is available or reimbursed.”
Decline in Serum Lysophosphatidylcholine Species in Patients with Severe Inflammatory Bowel Disease
Tews, H. C., Elger, T., Huss, M., Loibl, J., Kandulski, A., Müller, M., Höring, M., Liebisch, G., & Buechler, C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155485 · Cited by 4
“Patients with active IBD commonly exhibit elevated serum C-reactive protein (CRP), the most widely applied systemic marker of inflammation [32–34].”
Lei, M.-L., Bi, G.-W., Yin, X., Wang, Y., Sun, Z.-R., Guo, X., Zhang, H., Zhao, X., Li, F., & Yu, Y. (2025) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2025.1615047 · Cited by 4
“…serum biomarkers, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), anti-Saccharomyces cerevisiae antibodies (ASCA), and perinuclear antineutrophil cytoplasmic antibodies (p-ANCA), are limited by their low sensitivity and specificity (Sands, 2015; Sakurai and Saruta, 2023).”
Ondriš, J., Husťák, R., Ďurina, J., Jurkova, E. M., & Bošák, V. (2024) · Folia Biologica · doi:10.14712/fb2024070050248 · Cited by 5
Expert consensus on diagnostic guidelines for pediatric inflammatory bowel disease in Japan
Kudo, T., Arai, K., Iwama, I., Hagiwara, S., Ishige, T., Yokoyama, K., Kakuta, F., Jimbo, K., Kondou, H., Takaki, Y., et al. (2025) · Journal of Gastroenterology · doi:10.1007/s00535-025-02271-7 · Cited by 5
“Urine can be collected noninvasively and may be useful for diagnosing pediatric IBD [103].”
Is Eosinophilic Colitis a Forerunner of Inflammatory Bowel Disease?
Thirumal, P., Keerthivasan, S., & Senthamizhselvan, K. (2025) · Current Gastroenterology Reports · doi:10.1007/s11894-025-01009-y · Cited by 4
“However, CRP might be negative in patients with low disease activity and has decreased accuracy [39].”
Loosen, S. H., Hansen, F. J., Luedde, T., Roderburg, C., & Kostev, K. (2025) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2025-001886 · Cited by 4
The Association Between Crohn’s Disease and Patient Response to Yeast: A Review of the Literature
Zonna, X. C., Banta, C. W., & Hossein‐Javaheri, N. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15040073 · Cited by 4
Yarur, A. J., Chiorean, M. V., Allegretti, J. R., Cross, R., Ha, C. Y., Goetsch, M., McDonnell, A., Dalam, A. B., WU, J. M., Blanco, D. A., et al. (2024) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izae288 · Cited by 4
Zalecińska, A., Harasym, J., Dziendzikowska, K., Sikorska, K., & Gromadzka-Ostrowska, J. (2025) · Nutrients · doi:10.3390/nu17243812 · Cited by 4
“…cytokines (IL-1beta, IL-6, TNF-alpha) [34] and is an effective indicator for assessing the activity of this disease, especially in combination with other parameters such as the number of bowel movements, the presence of blood in the stool, body temperature, and blood count parameters [42].”
Yoshimura, S., Okata, Y., Ooi, M., Horinouchi, T., Iwabuchi, S., Kameoka, Y., Watanabe, A., Kondo, A., Uemura, K., Tomioka, Y., et al. (2024) · PubMed Central · doi:10.24546/0100486228 · Cited by 3
“…both PPV and NPV, compared to conventional serum ESR and CRP. Recently, serum LRG has been widely used as a marker for monitoring disease activity and diagnosing mucosal healing in adult UC and CD patients; however, few studies have demonstrated its use as a screening marker for IBD diagnosis (18).”
Fecal calprotectin as an inflammatory biomarker in small bowel Crohn disease
Sousa, M. I., Dias, E., Andrade, P., & Macedo, G. (2024) · Porto Biomedical Journal · doi:10.1097/j.pbj.0000000000000263 · Cited by 3
“14 Interestingly, FC has demonstrated better correlation with inflammatory status than CRP or leucocyte counts in these patients, 15-17 and recent prospective studies have suggested it may play an important role in SB CD, 18-20 even in the absence of colonic endoscopic abnormalities.”
BackgroundFu, Q., Vegesna, M., Sundararaman, N., Damoc, E., Arrey, T. N., Pashkova, A., Mengesha, E., Debbas, P., Joung, S. Y., Li, D., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202409446 · Cited by 8
Kaur, M., McFeeters, J., Satija, D., Skeans, J. M., Pusateri, A. J., Korman, A. M., & Kaffenberger, B. H. (2024) · Archives of Dermatological Research · doi:10.1007/s00403-024-03442-x · Cited by 3
Blood transcriptomics identifies FEZ1 as a potential biomarker for inflammatory bowel disease
Delkhah, A. M. D. (2025) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2025.109742 · Cited by 4
Rapo, M., Molander, P., af Björkesten, C.-G., Pakarinen, S., & Arkkila, P. E. T. (2025) · International Journal of Colorectal Disease · doi:10.1007/s00384-025-04829-6 · Cited by 2
Drug Repurposing to Inhibit Oncostatin M in Crohn’s Disease
Bahramimehr, F., Guthart, A., Kurz, S., Hai, Y., Dawood, M., Yücer, R., Shahhamzehei, N., Weiskirchen, R., Roth, W., Stremmel, W., et al. (2025) · Molecules · doi:10.3390/molecules30091897 · Cited by 2
“Our perspective is supported by the fact that oncostatin M has been identified as a predictive biomarker for the outcome of Crohn’s disease [57,58].”
Zhang, H., Ding, X., Xu, Y., Wu, J., Wang, Y., Liu, S., Yan, J., Liu, H., Tian, Z., & Liu, A.-L. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04125-1 · Cited by 2
Górecka, A., Jura-Półtorak, A., Szeremeta, A., & Komosińska‐Vassev, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262110439 · Cited by 2
Yao, L., Cao, Y., Bai, C., Liu, R., Yang, W., Chao, K., Huang, Z., Qiu, Y., Gao, X., Chen, M., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14227919 · Cited by 2
“It is commonly used in the evaluation of many inflammatory diseases and functions as an effective monitoring biomarker to assess patients in the active phase of IBD [31].”
Magro, F., Rogler, G., Feagan, B. G., Peyrin‐Biroulet, L., Oortwijn, A. F., Cougnaud, L., Faes, M., Bauer, Y., Randall, M. J., Rudolph, C., et al. (2026) · Journal of Crohn s and Colitis · doi:10.1093/ecco-jcc/jjaf228 · Cited by 2
Okegunna, Y., Sekar, M., Adriaans, G. M. C., Cloots, M., Zhang, J., Aliu, A., Hendrix, E. M. B., Romberg-Camps, M. J. L., Ardabili, A. R., Mujagic, Z., et al. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09750-8 · Cited by 3
El-Nady, M. A., Hefny, N. E. A. M. E., Fathy, H., Ali, W. A., & Ashmawy, A. M. (2023) · Gastroenterology Review · doi:10.5114/pg.2023.132932 · Cited by 4
“Blood tests such as C-reactive protein (CRP) and faecal calprotectin can indicate the presence of inflammation, but they do not provide information about the location or severity of inflammation [3, 4].”
BackgroundUrinary Hydroxyproline as an Inflammation-Independent Biomarker of Inflammatory Bowel Disease
Huss, M., Elger, T., Loibl, J., Kandulski, A., Binder, B., Stöckert, P., Mester, P., Müller, M., Buechler, C., & Tews, H. C. (2024) · Gastroenterology Insights · doi:10.3390/gastroent15020035 · Cited by 4
Fecal, Blood, and Urinary Biomarkers in Inflammatory Bowel Diseases
Bencardino, S., D’Amico, F., Zilli, A., Parigi, T. L., Allocca, M., Fiorino, G., Danese, S., & Furfaro, F. (2024) · Journal of Translational Gastroenterology · doi:10.14218/jtg.2024.00001 · Cited by 6
“92 Enhancing diagnostic accuracy through multi-target panels of biomarkers has demonstrated improved sensitivity and specificity.”
Diagnosis and Differentiation of Inflammatory Bowel Disease
Westfall, K. M., Charles, R., & Steinhagen, E. F. (2024) · Surgical Clinics of North America · doi:10.1016/j.suc.2024.09.005 · Cited by 2
Metabolite profiling in assessing ulcerative colitis activity: A systematic review
Cui, D., Han, X., Jin, J., Wang, Y., Chen, Z., Yang, G., & Jiang, M. (2025) · Human Nutrition & Metabolism · doi:10.1016/j.hnm.2025.200298 · Cited by 2
Fu, Q., Remes, P. M., Lee, J., Jacob, C., Li, D., Vegesna, M., Raedschelders, K., Haghani, A., Mengesha, E., Debbas, P., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202507610 · Cited by 3
Асхатовна, К. А., Khanafina, M. A., & Garina, G. A. G. (2023) · Педиатрическая фармакология · doi:10.15690/pf.v20i4.2605 · Cited by 2
Yan, J.-W., Nie, M., Zhang, H., Liu, Y.-M., & Tang, F. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i9.100607 · Cited by 2
“AI can analyze multiple biomarkers to monitor disease progression and response to treatment, thereby enhancing treatment precision and effectiveness[6,36].”
Herrero-Rodríguez, S., Martín-Cordero, L., Mayordomo, R., Gálvez, I., & Ortega, E. (2025) · Gastroenterología y Hepatología (English Edition) · doi:10.1016/j.gastrohep.2025.502494 · Cited by 1
Wu, H., Sun, Y., Tang, Z., Qin, X., Wang, Y., & Huang, Y. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s529537 · Cited by 2
“30 The diagnostic delay in our cohort underscores this issue, and the access of children at high risk of pediatric IBD to specialist resources may be limited.”
Zhang, Q., Liu, H., Liu, S., Zhu, S., Zhang, S., Yang, Z., & Wu, S. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003734 · Cited by 2
Alkrinawi, J., Alnees, M., Masu’d, M., Hamdeh, N. A., Fraitekh, Y. Z., Zahran, A., Najajra, D., Darwish, A., Kabaha, A. A. R., Daoud, A., et al. (2026) · BMC Gastroenterology · doi:10.1186/s12876-025-04584-6 · Cited by 2
Siddiqui, M. A., Agrawal, N., Gupta, S., Lanjhiyana, S. K., Jaiswal, M., & Gupta, V. (2026) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898814021126010005 · Cited by 2
Zhao, X., & Zhang, X. (2026) · BMC Gastroenterology · doi:10.1186/s12876-026-04738-0 · Cited by 1
“In addition to traditional biomarkers, some new factors, such as penetraxin-3 (PTX3) discovered by Chen et al. [20], have been identified as indicators of disease activity in patients with IBD.”
Vadarlis, A., Germanidis, G. S., Maris, T., Pramateftakis, M. G., & Chourdakis, M. (2026) · Digestive Diseases and Sciences · doi:10.1007/s10620-026-09880-z · Cited by 2
“Fecal calprotectin (FC) is a commonly used biomarker, reflecting inflammation and aiding in diagnosis, activity assessment, and predicting outcomes [10, 11].”
Ingestible smart capsules: from engineering innovation to GI drug delivery
Singh, D., Kumari, P., Singh, B., Sah, A., & Ghosh, B. (2026) · Biomedical Microdevices · doi:10.1007/s10544-026-00828-8 · Cited by 1
“Localization strategies validated in healthy volunteers perform unreliably in inflamed bowel (Sakurai and Saruta 2023).”
Barrientos, E. C., Tantucci, L., Cabrera, D., Fernandez, M. L., Fochesato, A., Delgado, A., Correa, S., Balderramo, D. C., & Romagnoli, P. A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146318 · Cited by 1
“Despite this growing burden, current diagnostic approaches remain suboptimal: clinical biomarkers lack adequate sensitivity and specificity for early detection, while definitive diagnosis requires invasive endoscopic, radiological, and histopathological evaluation [6].”
Krzystek‐Korpacka, M., Lewandowski, Ł., Bednarz‐Misa, I., Korpacki, A., & Neubauer, K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167217 · Cited by 1
“The ability to distinguish active UC from CD represents one of the five major unmet needs that biomarkers are expected to address in IBD [13].”
Today and tomorrow: the use of biomarkers in inflammatory bowel disease
Rowan, C. R., & Ingram, R. J. M. (2023) · Canadian IBD Today · doi:10.58931/cibdt.2023.1320 · Cited by 1
Moura, E. Q. D. A., Nunes, B. F., Bratti, L. D. O. S., & Filippin-Monteiro, F. B. (2024) · Clinical Immunology Communications · doi:10.1016/j.clicom.2024.02.001 · Cited by 1
Kim, H., Kim, Y. Z., Kim, S. Y., Choe, Y. H., & Kim, M. J. (2024) · Frontiers in Pediatrics · doi:10.3389/fped.2024.1479619 · Cited by 1
“Furthermore, the ESR re fl ects chronic or subacute in fl ammation, indicating a slower response to in fl ammation compared to CRP, which increases in response to the acute-phase reaction (27, 28).”
BackgroundHolistic Treatment of Inflammatory Disease for the Mobility Impaired
Laymon, M., & Laymon, K. (2023) · Rheumatica Acta Open Access · doi:10.17352/raoa.000015 · Cited by 1
Assessing endoscopic remission in small bowel Crohn's disease: Are markers enough?
Issa, I. A., & Issa, T. (2025) · World Journal of Gastrointestinal Endoscopy · doi:10.4253/wjge.v17.i4.106083 · Cited by 2
Capsule Endoscopy in Suspected and Established Small Bowel Crohn’s Disease
Mastronardi, M., & Cavalcanti, E. (2023) · IntechOpen eBooks · doi:10.5772/intechopen.112178
Khalitova, Y. A., Zhestkov, A. V., & Myakisheva, Y. V. (2023) · Terapevt (General Physician) · doi:10.33920/med-12-2311-03
Is fecal calprotectin a dependable indicator of activity in inflammatory bowel diseases?
Dragašević, S., Lalošević, M. S., Nikolić, A., Panić, N., & Milivojević, V. (2023) · Medicinska istrazivanja · doi:10.5937/medi56-46194
“Fecal calprotectin (FCP) is a commonly used biomarker of inflammation in the management of IBD (1, 2).”
BackgroundEvolution of Treatment Targets in Inflammatory Bowel Disease
Kyriacou, M., Vuyyuru, S. K., & Moran, G. W. (2023) · Medical Research Archives · doi:10.18103/mra.v11i11.4662
Diagnostic Delay in Crohn’s Disease: Reality Today and Strategies to Overcome It
Topličanin, A., & Milutinović, A. S. (2023) · Medical Research Archives · doi:10.18103/mra.v11i12.4969
Metadata
- Authors
- Sakurai, T., & Saruta, M.
- Affiliations
- Jikei University School of Medicine (JP)
- Corresponding author
- Sakurai, Toshiyuki
- Venue
- Digestion
- Publisher
- S. Karger AG
- Published
- 2022-11-18
- Volume
- 104
- Issue
- 1
- Pages
- 30-41
- ISSN
- 0012-2823 (ISSN-L)
- 1421-9867
- PMC
- PMC9843547
- OpenAlex
- W4309466247
- Cited by
- 156
- References
- 137
- Citations by year
- 2026: 43 · 2025: 48 · 2024: 42 · 2023: 23
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0/ (vor)
- creativecommons.org/licenses/by-nc/4.0/ (tdm)
- Locations
- Digestion (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Health Sciences › Medicine › Gastroenterology › Microscopic Colitis
- Keywords
- inflammatory bowel disease, biomarkers, mucosal healing, fecal calprotectin, C-reactive protein, LRG1, ASCA, antineutrophil cytoplasmic antibodies, fecal immunochemical test, disease activity monitoring, treatment response prediction, disease recurrence prediction, ulcerative colitis, Crohn's disease, non-invasive diagnosis, oncostatin M, microRNA
- MeSH terms
- C-Reactive Protein, Colitis, Ulcerative, Feces, Glycoproteins, Humans, Leucine, Severity of Illness Index, Inflammatory Bowel Diseases, Biomarkers, Leukocyte L1 Antigen Complex
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.